Humagrip, 16 tablets, Urgo

Humagrip, 16 tablets, Urgo

Read the leaflet carefully and completely before you start using this medicine, because it contains important information for you.
Always use this medicine as directed in this leaflet or as directed by your doctor or pharmacist.

Indications:
Short-term symptomatic treatment of flu-like conditions accompanied by headache and/or fever and the sensation of 'stuffy nose'. It is recommended only for adults and children over the age of 15.

Composition:

• 1 daily tablet contains: paracetamol 500 mg, pseudoephedrine hydrochloride 60 mg and excipients: microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, magnesium stearate, povidone K30.
• 1 capsule in the evening at bedtime contains: paracetamol 500 mg, chlorpheniramine maleate 4 mg and excipients: talc, sodium lauryl sulfate, colloidal anhydrous silicon dioxide, croscarmellose sodium, erythrosine (E127), indigotine (E132), titanium dioxide (E171). ,gelatine.
• Active substance: carbocisteinum.

Administration method:

• The maximum duration is 4 days. An interval between intakes of at least 4 hours will be observed.
• The recommended dose is one white daily tablet in the morning and one blue capsule in the evening before going to bed. If necessary, white tablets can be taken at lunch and in the evening, but do not exceed 3 white tablets and one blue capsule per day.

Contraindications:
Do not take HUMAGRIP tablets and capsules:

• if you are under the age of 15;
• if you are allergic to the active substances or any of the other components of this medicine;
• if you are breastfeeding;
• It is generally not recommended for use in pregnant women.

Precautions:
Before using HUMAGRIP tablets and capsules, talk to your doctor or pharmacist.

Pregnancy, breast-feeding and fertility:

• If you are pregnant or breast-feeding, think you may be pregnant or are planning to become pregnant, ask your doctor or pharmacist for advice before taking this medicine.
• The presence of pseudoephedrine requires the avoidance of HUMAGRIP during pregnancy.
• Experimental and clinical studies conducted on several hundred pregnant women ruled out the malformative effect of pseudoephedrine. Fetal toxicity is related to the pharmacological action of the molecule and may manifest as fetal tachycardia and hyperactivity.
• Accordingly, pseudoephedrine can be prescribed during pregnancy only if absolutely necessary and only on the recommendation of the doctor. It is contraindicated when there is fetal distress or hypertensive maternal pathology.
• HUMAGRIP is contraindicated during breast-feeding because pseudoephedrine is excreted in breast milk and may cause tachycardia in the infant.

Driving vehicles and using machines:
Drivers and people who operate machinery should be warned that HUMAGRIP may cause drowsiness or slight agitation.

Presentation:
12 tablets and 4 capsules